Pulmatrix, Inc. (NASDAQ:PULM) – Research analysts at Zacks Investment Research lifted their FY2017 earnings estimates for shares of Pulmatrix in a research report issued on Tuesday. Zacks Investment Research analyst A. Dushyanth now anticipates that the biotechnology company will post earnings of ($1.00) per share for the year, up from their previous estimate of ($1.20). Zacks Investment Research also issued estimates for Pulmatrix’s Q4 2017 earnings at ($0.30) EPS, FY2018 earnings at ($0.80) EPS and FY2019 earnings at ($0.80) EPS.

Separately, Dawson James reiterated a “buy” rating on shares of Pulmatrix in a research note on Wednesday, September 27th.

TRADEMARK VIOLATION NOTICE: “FY2017 Earnings Estimate for Pulmatrix, Inc. (PULM) Issued By Zacks Investment Research” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/17/fy2017-earnings-estimate-for-pulmatrix-inc-pulm-issued-by-zacks-investment-research.html.

Shares of Pulmatrix (NASDAQ PULM) remained flat at $$1.62 during midday trading on Friday. 71,719 shares of the company’s stock traded hands, compared to its average volume of 1,883,850. Pulmatrix has a 52 week low of $0.50 and a 52 week high of $6.98.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08. The company had revenue of $0.34 million during the quarter.

A hedge fund recently raised its stake in Pulmatrix stock. Vanguard Group Inc. increased its stake in Pulmatrix, Inc. (NASDAQ:PULM) by 8.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 99,758 shares of the biotechnology company’s stock after acquiring an additional 7,351 shares during the period. Vanguard Group Inc. owned approximately 0.52% of Pulmatrix worth $240,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 21.49% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.

Receive News & Stock Ratings for Pulmatrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc. and related stocks with our FREE daily email newsletter.